ArticleBMC infectious diseases2019

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.

Alberto Borghetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.